NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call summary and Q&A session reveal strong financial metrics, positive cash flow, and operational efficiencies. The launch of new products and services, such as RaDaR ST and PanTracer LBx, coupled with a strategic focus on high-margin business, indicate growth potential. The company's guidance and confidence in future growth, despite some uncertainties, suggest a positive outlook. Given the market cap of $1.7 billion, the stock is likely to react positively, falling into the 'Positive' category (2% to 8%) over the next two weeks.

Key Financial Performance

Q4 Total Revenue $190 million, representing double-digit growth of 11% year-over-year. The growth was driven by effective execution of key commercial strategies, enabling volume and share gains in key segments.

Clinical Business Revenue Increased 16% year-over-year in Q4. This was driven by effective execution of key commercial strategies, enabling volume and share gains in key segments.

NGS Revenue Growth 23% year-over-year in Q4, well ahead of the NGS market growth rate. This was supported by the contribution of 5 NGS products launched in 2023, which accounted for 23% of clinical revenue in the quarter.

Full Year Total Revenue $727 million, representing 10% growth over full year 2024. Growth attributed to deeper penetration into the community setting, a shift to higher-margin modalities, and execution of revenue cycle management initiatives.

Adjusted Gross Profit (Q4) Improved by $5.8 million or 7% year-over-year. This improvement was driven by strong clinical revenue growth.

Adjusted EBITDA (Q4) $13.4 million, up 10% year-over-year. This marks the 10th consecutive quarter of positive earnings, with sequential improvement in margins each quarter in 2025.

Clinical Test Volumes (Q4) Increased by 11% year-over-year. Growth was impacted by intentional rationalization of exposure to higher volume, lower-value test clients.

Average Revenue Per Clinical Test (Q4) Increased by 5% year-over-year. Growth was driven by a larger percentage of higher-value tests, managed care pricing increases, and revenue cycle management initiatives.

Non-Clinical Revenue (Q4) Declined by over 25% year-over-year. No specific reasons for the decline were mentioned.

Full Year Adjusted Gross Profit $335 million, representing an 8% increase year-over-year. Growth was driven by deeper penetration into the community setting and a shift to higher-margin modalities.

Full Year Adjusted EBITDA $43.4 million, representing a 9% increase year-over-year. Growth was attributed to deeper penetration into the community setting and execution of revenue cycle management initiatives.

Cash Flow from Operations (Q4) Positive $1 million. This was supported by strong clinical revenue growth and operational efficiencies.

Cash Flow from Operations (Full Year) Positive $5 million, with free cash flow improving by over 35% compared to 2024. This was driven by operational efficiencies and revenue growth.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

RaDaR ST MRD assay: Prepared for a full clinical launch this month. Demonstrated 97% concordance and equivalent sensitivity with RaDaR 1.0. Secured MolDx reimbursement for HPV-negative head and neck cancer and a subset of breast cancers. Two additional solid tumor cancer indications submitted for MolDx approval.

PanTracer Portfolio: Expanded with the launch of PanTracer Pro, integrating broad genomic profiling with diagnosis-directed IHC and ancillary testing. PanTracer LBx submitted for MolDx clinical reimbursement coverage. PanTracer tissue saw strong growth, nearly doubling test volumes year-over-year.

Community Oncology Market: Achieved deeper penetration with 14% growth in pathologists and oncologists ordering 5+ tests. Approximately 40% of active pathologists and oncologists ordered 5+ tests in 2025. Expanded sales force by 35 oncology sales specialists.

MRD Market: Expanding sales force to penetrate head and neck market. Plans to add 25 oncology sales specialists by Q3 2026 to support RaDaR ST adoption.

Operational Efficiencies: Achieved synergies from Pathline acquisition, expected to be accretive to profitability in 2026. Implemented tools to enhance sales productivity and customer workflows.

Revenue Cycle Management: Managed care pricing increases and RCM initiatives contributed to higher average revenue per clinical test (AUP).

Shift to Higher-Value Testing: Intentionally prioritized higher-value tests, leading to AUP expansion as a significant revenue growth driver.

Investment in R&D: Focused on next-generation MRD assay development, targeting a clinical launch by 2028. Continued investment in PanTracer and RaDaR ST product lines.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Reimbursement Decisions: The timing and outcome of reimbursement decisions could materially differ from expectations, impacting financial performance and strategic objectives.

Market Penetration: Over half of practicing providers have not yet been brought over to NeoGenomics, indicating challenges in fully penetrating the market.

Pathline Acquisition Synergies: Operational efficiencies and synergies from the Pathline acquisition are anticipated but not yet fully realized, posing a risk to profitability.

Regulatory Approvals: Pending MolDx approvals for additional cancer indications and PanTracer LBx test could delay market expansion and revenue growth.

Weather Impact: Extreme weather conditions have caused provider office closures, impacting Q1 volumes and revenue.

Non-Clinical Revenue Decline: Non-clinical revenue has declined by over 25% in Q4 and is expected to remain soft, potentially affecting overall financial performance.

Sales Force Expansion: The addition of 25 oncology sales specialists for RaDaR ST and other initiatives may not yield immediate returns, impacting short-term financials.

Product Development Costs: Ongoing R&D investments in next-generation MRD and other products could strain financial resources without guaranteed returns.

Economic Pressures on Community Oncologists: Community oncologists face operational, economic, and time pressures, which could affect their adoption of NeoGenomics' solutions.

Competition: Late market entry for some NGS products compared to peers could hinder market share growth.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

2026 Revenue Guidance: NeoGenomics expects revenues of $793 million to $801 million for 2026. The midpoint assumes RaDaR ST revenue in mid-single-digit millions for approved indications, modest revenue contribution from PanTracer liquid, and sustained softness in nonclinical revenue.

Quarterly Revenue Growth Expectations: Revenue growth is expected to be approximately 10% year-over-year in Q1, 8%-9% in Q2, 9%-10% in Q3, and slightly above 10% in Q4 of 2026.

Adjusted EBITDA Guidance: Adjusted EBITDA is projected to be in the range of $55 million to $57 million for 2026, representing year-over-year growth of approximately 27% to 31%. Growth is expected to be in the low 20% range in Q1 and Q2, and low 30% range in Q3 and Q4.

RaDaR ST Revenue Contribution: RaDaR ST is expected to contribute modest revenue in 2026 as adoption ramps and reimbursement approvals are gained for additional indications. Revenue growth from RaDaR ST is anticipated to accelerate in 2027 and beyond.

PanTracer Liquid Revenue Contribution: PanTracer liquid is expected to contribute modest revenue in 2026, contingent on favorable MolDx reimbursement coverage.

Sales Force Expansion: NeoGenomics plans to add more than 25 oncology sales specialists by Q3 2026 to support the RaDaR ST launch and market penetration.

Next-Generation MRD Development: NeoGenomics is investing in next-generation MRD assays, with product development ongoing, data generation and MolDx submissions planned for 2027, and a potential clinical launch as early as 2028.

Free Cash Flow Goals: The company aims to become free cash flow positive in 2026 through strategic investments in sales, marketing, and R&D, while improving liquidity.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Can you provide more specifics about the launch of RaDaR ST, including timing and sales rep focus?

A:The full launch of RaDaR ST is planned for the end of this month, focusing initially on head and neck indications and subsets of breast cancer (HPV-negative and HR HER2-negative breast). Additional indications are expected in the latter half of the year, potentially generating revenue in 2026. The sales team is expanding to target these areas, with a small team dedicated to ENTs for head and neck indications.

Q:Can you quantify the impact of exiting low-value business on clinical volume and future volume growth?

A:Exiting low-value business has shifted the model to focus on higher AUPs and margins. Sequential volume growth was slightly down in Q4, and Q1 is expected to follow a similar trend. Year-over-year volume growth is expected to be flat in Q2, with growth resuming in Q3 and Q4.

Q:What are the underlying assumptions for core clinical business growth in 2026?

A:The core clinical business is expected to grow at about 11%, with the overall company growth at around 10%. This includes contributions from Pathline and modest revenue from LBx in the second half of the year, assuming MolDx approval.

Q:What is the status and impact of the LIMS rollout?

A:The LIMS rollout is a multiyear process aimed at improving margins and efficiency. Initial benefits will be seen in 2026, with more pronounced impacts in 2027 and 2028. The focus for 2026 is on molecular and accessioning workflows, with operational efficiencies and better analytics already being realized.

Q:What is the outlook for pharma ordering in 2026, and which products will lead?

A:Pharma ordering is expected to see modest erosion in 2026, with a return to growth anticipated in 2027. RaDaR ST is expected to be a key growth driver, with robust interest and an expanding opportunity pipeline.

Q:What is the confidence level in achieving mid-single-digit million revenue for RaDaR in 2026, and what is the expected mix between clinical and pharma?

A:There is high confidence in achieving this target, with an initial heavier contribution from pharma due to longer clinical launch timelines. Clinical contributions are expected to build in the latter half of the year.

Q:What is the potential for continued ASP growth in 2026?

A:ASP growth is expected to continue in the upper single-digit range, driven by the shift to NGS, direct line bill pricing increases, managed care pricing increases, and other RCM initiatives.

Q:What is the competitive landscape for tissue and liquid CGP in the community setting?

A:The competitive landscape remains consistent, with NeoGenomics focusing on actionability and high service levels. The company is seeing success in both tissue and liquid CGP, leveraging its broad portfolio to simplify workflows for physician practices.

Q:What is the expected impact of the sales force expansion on productivity and revenue?

A:The expanded sales force is now at full productivity, contributing to success in H2 2025 and expected to drive growth in 2026. The focus is on therapy selection and supporting the RaDaR ST launch.

Q:What is the expected NGS growth in 2026?

A:NGS growth is expected to be at least 23%, similar to 2025, with potential upside depending on MolDx timing for PanTracer LBx.

Q:What is the expected gross margin improvement in 2026?

A:Gross margins are expected to improve by 100 to 120 basis points, driven by price increases, a shift to high-value tests, and operational efficiencies.

Q:Review of Unclear Management Responses

A:Management avoided providing specific details on the exact timing of MolDx approvals for LBx and RaDaR ST, as well as the precise financial impact of the LIMS rollout in 2026. They also did not quantify the expected revenue split between clinical and pharma for RaDaR ST or provide detailed competitive insights for CGP in the community setting.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

NEO Transcript

NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript

Positive2-17

NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Neutral1-14

NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript

Unknown10-28

The earnings call summary presents a mixed picture. While there are positive elements such as NGS growth and new product launches like PanTracer, there are also challenges like revised revenue guidance due to pharma uncertainties and potential negative EBITDA impact from Pathline integration. The Q&A session highlighted management's optimism but also revealed some vagueness in responses, particularly around timelines and competitive positioning. Given the company's small-cap status, the stock is likely to remain stable, leading to a neutral prediction.

NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript

Unknown7-29

The earnings call summary shows mixed signals. While the company has a strong product development and partnership strategy, financial performance is affected by delays and market challenges. The Q&A reveals management's confidence in guidance despite uncertainties, but also highlights risks such as litigation and limited visibility in pharma services. The positive aspects such as the Pathline acquisition and NGS growth are balanced by cautious guidance and challenges in the pharma market. Given the company's market cap, the stock price is likely to remain stable in the short term, leading to a neutral prediction.

NEO Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.